Prospective Evaluation of Systemic Coagulation Function During Anti-Amyloid Monoclonal Antibody Therapy in Alzheimer’s Disease
Background: Anti-amyloid monoclonal antibodies such as lecanemab are increasingly used to treat Alzheimer’s disease (AD) and are associated with amyloid-related imaging abnormalities (ARIA), including hemorrhagic findings (ARIA-H). Whether anti-amyloid therapy is associated with systemic alterations in coagulation func...